Nasus Pharma Ltd · NYSE American: NSRX · Tel Aviv, Israel
Epinephrine as a powder in the nose, measured against the autoinjector.
Nasus Pharma is a clinical-stage company developing intranasal powder medicines for emergencies. Its lead candidate, NS002, is an epinephrine powder for anaphylaxis. The company has no approved product and no revenue, and its auditor’s report raises substantial doubt about its ability to continue as a going concern.
- Annual and special general meeting of shareholders (scheduled)
- Start of a pivotal study of NS002, as planned by the company and subject to regulatory alignment
Filings reviewed through the 6-K filed Sep 18, 2026. Amounts in US dollars. No share price is shown.
Phase 2: median time for blood epinephrine to reach 100 pg/mL
Open-label study of 50 healthy adults with allergic rhinitis, in Canada; p=0.033. These are blood levels, not clinical outcomes, and the figures are the company’s. A later release gives 3.47 minutes for EpiPen. 6-K, Mar 16, 2026 20-F
At a glance
The position, in six facts
- Cash, restricted cash and short-term deposits, Jun 30, 2026
- $11.9M
- Reported as $11,904 thousand. The company puts it at about $10.3 million on August 17 and says that is enough “through the second quarter of 2027”. Net cash used in operations was $6.0 million in the six months, about $1.0 million a month (derived). 6-K, Aug 17, 2026
- Net loss, six months to Jun 30, 2026
- $5.9M
- Against $1.3 million a year earlier. Research and development was $2,589 thousand (from $289 thousand) and general and administrative $3,452 thousand (from $528 thousand). 6-K
- Revenue to date
- None
- The auditor’s report cites “the Company’s lack of revenues”. The 20-F says “We currently have no FDA-approved products.” 20-F
- Shares issued, Jun 30, 2026
- 11,710,808
- Up from 9,015,383 at Dec 31, 2025. The increase of 2,695,425 equals the shares sold in the February 2026 private placement, which also gave the investors warrants over as many more shares. The August 17 press release’s 11,070,458 is the six-month weighted average. 6-K
- Team, Dec 31, 2025
- 7 full-time
- Plus 2 service providers. The 20-F says “We are currently a virtual company.” 20-F
- Lead program
- NS002
- The Phase 2 pharmacokinetic study has reported. On Sep 14, 2026 the company announced that the FDA had cleared its IND application; it plans a pivotal study in the fourth quarter of 2026. 6-K, Sep 14, 2026
The need
A rescue medicine that many patients do not carry
Every figure in this section is as stated in the company’s 20-F, which attributes most of them to third-party research. None has been verified here.
“out of approximately 7 million patients prescribed with Epinephrine in 2023, approximately 50% do not carry Epinephrine”
Cantor Fitzgerald Research and Raymond James Research, 2024, as cited in the 20-F
Bars are drawn to the approximate values. The 20-F attributes them to Cantor Fitzgerald Research and Raymond James Research, 2024.
How common
The 20-F cites World Allergy Organization guidance (2020) for a global incidence of 50-112 anaphylaxis episodes per 100,000 persons per year, with recurrence in 26.5-54.0% of patients. It separately states a lifetime prevalence of about 2% in the U.S. and up to 3% in Europe, without naming a source in that passage. 20-F
How it is treated today
Epinephrine is the first-line therapy. The 20-F describes the typical two-autoinjector package as “quite large and cumbersome, requiring a special carrying bag” and cites a 2024 drugs.com study for prices per two-autoinjector package of $650 to $700 for EpiPen and $347 to $481 for generics. 20-F
The company’s press releases also cite a “$2 billion market”. They give no source for it, so this page does not use it. The 20-F names competing programs, including an FDA-approved intranasal liquid epinephrine product; see the disclosures.
Platform
A powder rather than a liquid, built from two particle populations
What the company says it has made
The 20-F describes the company’s “proprietary powder composition for intranasal delivery, Nasax, is comprised of uniform spherical APIs and carriers approved for inhalations”. Its patented process, the filing says, “creates a unique combination of two homogenous particle populations”: small, unified active particles for stable and repeatable absorption, and large lactose particles that “serve as disaggregants and carriers for the powder into the nose”. 20-F
Why powder, in the company’s argument
The 20-F says “Most intranasal emergency drugs approved by the FDA in recent years are liquid based. Powder nasal spray products are extremely rare”, and that its powder epinephrine is “stable and devoid of the stability issues of liquid-based Epinephrine products in the market”. These are the company’s statements. 20-F
The device, and who makes it
The delivery system is Aptar’s intranasal Unit Dose Spray. The 20-F says Aptar “is our sole supplier for supply of its intranasal Unit Dose Spray product”, and on October 6, 2025 the company signed a new master services agreement, a schedule of work and a short-form supply agreement with Aptar France. 20-F 6-K, Oct 8, 2025
From a Nasal Cast graphic published by Aptar, as described in the 20-F, using generic lactose powder and a generic liquid in Aptar’s device (n=6). The 20-F says it “does not specifically reflect the distribution of our powder formulation”: it is not a result for NS002.
Phase 2 data
What was measured, and what it does not show
Top-line results as announced on Mar 16, 2026, repeated in the 20-F. The company describes the study as “open-label, fixed-sequence”, in 50 healthy adults with a history of allergic rhinitis, each given NS002 and an EpiPen injection.
| Measure | NS002 | EpiPen | p-value |
|---|---|---|---|
| Median time to 100 pg/mL epinephrine in blood | 1.69 min | 3.42 min | 0.033 |
| Share of participants at the threshold by 2.5 minutes | 67.4% | 27.1% | 0.0001 |
| Share at the threshold by 5 minutes | 88.4% | 64.6% | 0.0081 |
| Share at the threshold by 10 minutes | about 95% | not stated | not stated |
| Median time to peak concentration | 15 min | 19.8 min | not stated |
| Total exposure in the first 10 minutes (called statistically significant in the first 5 to 10 minutes) | about 50% higher | comparator | none given |
Pipeline
One program in the clinic, one paused, three before it
Stages are the company’s, as stated in the 20-F and later 6-Ks. A mark on the ladder shows the stage the filing describes, not a prediction. Where the 20-F describes a program two ways, both are shown.
| Program | For | Stage as stated | Stage |
|---|---|---|---|
| NS002Intranasal epinephrine | Anaphylaxis (type 1 severe allergies) | The 20-F lists a completed Phase 2 and the IND clearance was announced Sep 14, 2026; the study approved in the IND compares self-administration with administration by a health care professional. A pivotal study is planned in addition, for the fourth quarter of 2026, with topline data in the first quarter of 2027, subject to regulatory alignment. 6-K 6-K 6-K | |
| NS001Intranasal naloxone | Opioid overdose | The 20-F lists a completed pivotal study; the interim notes say a Phase 3 trial was completed. Development is paused and the company is evaluating partnering and strategic alternatives. 6-K | Paused, no stage mark |
| NS003Intranasal ondansetron | Chemotherapy-induced and post-operative nausea and vomiting | Preclinical. Positive animal pharmacokinetic and safety results announced Jun 9, 2026; a first-in-human pharmacokinetic study was planned for the third quarter of 2026. 6-K | |
| NS004Intranasal atropine | Organophosphate poisoning in the 20-F overview; a metabolic indication in its business section | Preclinical. The 20-F describes it as intranasal atropine in one place and, in another, as “an injectable product commonly used in the metabolic space” with first-in-human phase 1 studies expected in the second half of 2026; the March 25 release says “NS004 (metabolic)”. 20-F 6-K | |
| NS005Intranasal midazolam | Acute seizures in the 20-F overview; cardiovascular in its business section | Preclinical or earlier. The 20-F describes it as intranasal midazolam in one place and, in another, as “an oral product commonly used in the cardiovascular diseases” at the “formulation development stage”. 20-F 6-K |
Stage boxes, left to right: preclinical, Phase 1, Phase 2, pivotal. A filled box is the stage the filing describes; a dashed box is a stage the company has planned but not begun.
The 20-F says the company “currently intend[s] to focus our development and regulatory approval efforts on our Intranasal Epinephrine and POC programs”.
The dated record
Thirteen months, in the filings
From the IPO to the latest filing reviewed, with the plans the company has announced marked as plans.
Shares begin trading on NYSE American
The initial public offering of 1,250,000 ordinary shares at $8.00 closed on August 14. A partial over-allotment (3,824 shares, Sep 30) brought gross proceeds to about $10 million.
New agreements with Aptar France
A new master services agreement, a schedule of work for the epinephrine program and a short-form supply agreement, replacing the 2019 master services agreement.
First participant dosed in the Phase 2 study
The Phase 2 study of NS002 against EpiPen, in 50 healthy adults in Canada, began dosing.
Interim Phase 2 results
The company reported 91% of participants at the 100 pg/mL threshold at 5 minutes with NS002 and 67% with EpiPen.
Private placement signed
2,695,425 shares with warrants for as many more, at a combined $5.565; about $15.0 million gross. The 20-F gives the closing as February 12; the proxy statement gives February 13.
Phase 2 topline results
Median 1.69 minutes to the threshold against 3.42 minutes for EpiPen, p=0.033.
NS003 preclinical results
A preclinical pharmacokinetic and safety study of intranasal ondansetron powder.
CEO transition
Dan Teleman resigns as CEO and director (effective Jul 22); Brendan P. O’Grady is appointed CEO from Jul 27.
First-half 2026 results
Six-month net loss $5.9 million; cash, restricted cash and short-term deposits $11.9 million at Jun 30.
CFO to leave
Eyal Rubin resigns effective Sep 18; Oren Elmaliach, Director of Finance, becomes interim CFO.
FDA clearance of the NS002 IND announced
The company announced that the FDA had cleared its IND application. It says a pivotal study is planned for the fourth quarter of 2026, with topline data in the first quarter of 2027.
At-the-market sales agreement
An agreement with BTIG, LLC to sell ordinary shares from time to time; the company is not obliged to sell.
Scheduled: annual and special general meeting
2:00 p.m. Israel time, record date Sep 14, 2026. Five proposals are put to a vote; see the Governance section. Not yet held at the time of the latest filing reviewed.
Planned by the company: pivotal study of NS002
The company plans to start a pivotal study in the fourth quarter of 2026 and expects topline data in the first quarter of 2027, “subject to regulatory alignment”. These are plans, not results.
Financials
Results, balance sheet and cash
US dollars, in thousands as reported. Annual figures are audited, from the 20-F filed Mar 25, 2026. Six-month figures are unaudited, from the 6-K filed Aug 17, 2026. The company reports no revenue.
Research and development General and administrative. The six-month bars are half-year totals on the same scale. Related parties accounted for $653 thousand of FY2025 research and development and $1,025 thousand of general and administrative expense.
The company says its cash “will be sufficient to fund its operations through the second quarter of 2027”, and the 20-F says “Additional funding will be required”. The August 17 bar is the company’s approximate figure of $10.3 million, not a balance-sheet date.
The results table scrolls sideways on a phone.
| Line | FY2023 | FY2024 | FY2025 | H1 2025 | H1 2026 |
|---|---|---|---|---|---|
| Research and development | 567 | 335 | 2,237 | 289 | 2,589 |
| General and administrative | 580 | 743 | 2,667 | 528 | 3,452 |
| Operating loss | (1,147) | (1,078) | (4,904) | (817) | (6,041) |
| Net loss | (1,051) | (1,532) | (5,856) | (1,252) | (5,942) |
| FY2024 | FY2025 | H1 2025 | H1 2026 |
|---|---|---|---|
| (665) | (4,918) | (433) | (6,036) |
| Line | Dec 31, 2024 | Dec 31, 2025 | Jun 30, 2026 |
|---|---|---|---|
| Cash and cash equivalents | 284 | 1,237 | 7,818 |
| Restricted cash | 27 | 54 | 86 |
| Short-term deposits | none | 3,049 | 4,000 |
| Total assets | 717 | 5,004 | 12,449 |
| Total liabilities | 3,929 | 2,236 | 1,453 |
| Accumulated deficit | (12,664) | (18,520) | (24,462) |
| Total equity (deficit) | (3,212) | 2,768 | 10,996 |
Dec 31, 2025 balances are as shown in the 6-K; the Dec 31, 2024 cash total is the 20-F’s $311 thousand. Loss per share was $0.54 for the six months to Jun 30, 2026 and $0.17 for the same period of 2025. Annual per-share figures are left out: the 20-F reports FY2025 loss per share as $(0.72) in one table and $(0.73) in another. Liabilities held for discontinued operations were $435 thousand at Jun 30, 2026.
Material disclosures
What a reader should know before relying on any figure above
Taken from the company’s own filings, with the filing beside each item.
Going-concern doubt
The auditor’s report says “the Company’s lack of revenues and accumulated operating losses raise substantial doubt about its ability to continue as a going concern”. The 20-F adds: “Additional funding will be required to complete our research and development and clinical trials, to attain regulatory approvals, to begin the commercialization efforts of our products and to achieve a level of sales adequate to support our cost structure.” The interim statements for the six months to June 30, 2026 say management concluded “there is substantial doubt about the Company’s ability to continue as a going concern”. 20-F 6-K, Aug 17, 2026
Cash against the plan
The company held $11,904 thousand in cash, restricted cash and short-term deposits at June 30, 2026 (the company puts it at about $10.3 million at August 17). It says this is “sufficient to fund its operations through the second quarter of 2027”. Net cash used in operating activities was $6,036 thousand in the six months ended June 30, 2026, about $1.0 million a month on average (derived). A page observation: the company’s own timeline puts topline data from the planned pivotal study in the first quarter of 2027, the quarter before the one in which its stated runway ends. The 6-K adds that “our operating plans may change” and “we may need to seek additional funds”. 6-K, Aug 17, 2026 6-K, Sep 14, 2026
No approved product, and one lead candidate
The 20-F says “We currently have no FDA-approved products.” It plans to seek approval of NS002 under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, “though the FDA may not agree our candidates satisfy the requirements”. The 20-F said an IND application had not yet been made; on September 14, 2026 the company announced that the FDA had cleared it. The release says the study approved in the IND will compare self-administration with administration by a health care professional, and that the pivotal study is planned “in addition to” it. The company’s December 22, 2025 shareholder letter planned pivotal study initiation for the third quarter of 2026; the current plan is the fourth quarter. NS001, the intranasal naloxone program, is paused while the company looks for partners. The other programs are described as preclinical or earlier. 20-F 6-K, Sep 14, 2026 6-K, Dec 22, 2025
Competing programs, including an approved nasal product
The 20-F lists competing programs. Two are developing intranasal liquid epinephrine: ARS Pharmaceuticals, Inc. “(whose product, Neffy, was recently approved by the FDA)” and Bryn Pharma, LLC. Orexo is developing a powder epinephrine, and Aquestive Therapeutics a sublingual film. The Phase 2 comparison on this page is against the EpiPen autoinjector, not against an approved nasal product. 20-F
What the Phase 2 numbers are, and are not
The Phase 2 study reported on March 16 was, in the company’s words, “open-label, fixed-sequence”; it enrolled 50 healthy adults with a history of allergic rhinitis and measured the pharmacokinetic profile of NS002 against EpiPen. It reports blood levels, not clinical effect in people having an anaphylactic reaction. The 20-F says “None of the studies of NS002 were powered for statistical significance. In trials not powered for statistical significance, there is a high chance that observed effects may not be real due to small sample size.” It also describes an earlier twelve-patient pilot study and a twelve-patient Phase 2 study. The comparator’s median time to the threshold is 3.42 minutes in the March 16 release and the 20-F, and 3.47 minutes in the September 14 release; the January interim figures (91% and 67% at 5 minutes) differ from the final (88.4% and 64.6%). The results are the company’s and are not FDA findings. 6-K, Mar 16, 2026 20-F 6-K, Sep 14, 2026 6-K, Jan 20, 2026
Dilution, warrants and an at-the-market program
Shares issued rose from 9,015,383 at December 31, 2025 to 11,710,808 at June 30, 2026, an increase of about 30% (derived) that equals the 2,695,425 shares sold in the February private placement. The investors also hold warrants over 2,695,425 shares at $6.53, which expire at the earlier of two years from issuance and 30 trading days after the company announces topline results of its pivotal study; exercised in full for cash they would bring in about $17.6 million (2,695,425 times $6.53; the company states the same figure). The IPO price was $8.00 and the private placement price $5.565 per share and warrant. On September 18, 2026 the company agreed an at-the-market program with BTIG, LLC; the 6-K gives no dollar amount and says the company “is not obligated to sell any Ordinary Shares”. The press release of August 17 gives 11,070,458 as the shares outstanding at June 30; the interim statements show that figure as the six-month weighted average and 11,710,808 shares issued at June 30. The articles set the registered share capital at 50,000,000 ordinary shares. Share options over 817,567 shares and underwriter warrants over 37,614 shares, exercisable at $10.00, were excluded from the six-month diluted loss per share as anti-dilutive. 6-K, Feb 12, 2026 6-K, Aug 17, 2026 6-K, Sep 18, 2026 6-K, Mar 6, 2026
A new CEO, a departing CFO and votes on pay
Both top executive roles changed within about two months. Dan Teleman resigned as CEO and director under a mutual separation agreement effective July 22, 2026, Brendan P. O’Grady started as CEO on July 27, and CFO Eyal Rubin resigned effective September 18 with the Director of Finance, Oren Elmaliach, as interim CFO. At the October 8 meeting shareholders vote on the new CEO’s package (base salary $500,000, a bonus of up to 50%, a $750,000 transaction bonus on a sale or change of control, and options over up to 280,000 shares at stepped prices of $3.50, $4.25 and $5.00) and on $70,000 of a $100,000 one-time bonus for the former CEO, which the proxy statement links to his contribution to the private placement. Proposals 3 and 4 need a “Special Majority” as the proxy statement defines it. Each resignation 6-K says the departure was not related to a disagreement with the company, and the CFO is leaving “to pursue a new opportunity outside of the life science industry”. 6-K, Jul 28, 2026 6-K, Aug 19, 2026 6-K, Sep 4, 2026
Related parties and control
Of FY2025 research and development expense of $2,237 thousand, $653 thousand was with related parties, and $1,025 thousand of $2,667 thousand of general and administrative expense; in the six months to June 30, 2026 the amounts were $320 thousand and $839 thousand. The 20-F’s table of directors marks co-founders Udi Gilboa and Dr. Dalia Megiddo as “Service Provider”. The directors and executive officers as a group (8 people) held 45.9% of the shares at March 25, 2026, and the three directors with the largest percentage holdings each held more than 12%. Formulex Pharma Innovations Ltd, owned by shareholders the interim statements name as Mr. Gilboa, Dr. Megiddo and Dr. Hershman, licenses a dry-powder patent to the company under a May 2019 agreement. Mr. Gilboa’s fees for the six months to June 30, 2026 include a one-time bonus of $277 thousand, which the statements describe as 2% of the private placement’s aggregate net proceeds. The 20-F also describes loans to the company in 2022 and 2023 from directors and shareholders; the February 2023 loan was discharged in August 2024 by issuing SAFEs (simple agreements for future equity), which converted into ordinary shares at the IPO. 20-F 6-K, Aug 17, 2026
A virtual company that depends on third parties
The 20-F says “We are currently a virtual company” and, as of December 31, 2025, “we employed seven full-time employees, two of which are members of senior management, in addition to two service providers”. It has no manufacturing facilities and relies on third parties; Aptar “is our sole supplier for supply of its intranasal Unit Dose Spray product, or UDS, to be the delivery system for our Intranasal Epinephrine powder and Intranasal Naloxone powder”. Under the supply agreement signed on October 6, 2025, and subject to FDA approval of the epinephrine program, Aptar France will supply the devices exclusively and the company commits to buy 100% of its requirements for epinephrine from it. The company also agreed to staged fees, milestone payments on NDA submission and approval, and royalties for seven years from the first commercial sale; the same agreements ended the 2019 master services agreement and settled outstanding disputes. 20-F 6-K, Oct 8, 2025
Material weaknesses in internal control
The 20-F says “We have identified material weaknesses in our internal control over financial reporting.” It describes moving bookkeeping and accounting functions that had been outsourced to third-party service providers in-house, and says “We cannot assure investors that our future remediation plan will be sufficient to establish and maintain effective internal control over financial reporting”. The CFO who joined in November 2025 is leaving effective September 18, 2026. 20-F 6-K, Aug 19, 2026
Operations in Israel
The company was incorporated in Israel in 2019 and has its mailing address in Tel Aviv. The 20-F carries a separate group of risk factors on Israeli law and its operations in Israel, and its forward-looking-statements list includes political and economic conditions “related to recent unrest and actual or potential armed conflict in Israel and other parts of the Middle East, such as the multi-front war Israel is facing”. As a foreign private issuer the company files Form 20-F and Form 6-K rather than Forms 10-K and 10-Q. 20-F
A discontinued product and its liabilities
The company wound down its earlier product, Taffix, from the end of 2021: “As of December 2022, the Company is no longer engaged in the development, production, marketing or sales of Taffix.” Liabilities classified as discontinued operations were $435 thousand at June 30, 2026. 20-F 6-K, Aug 17, 2026
Statements that come from the company, not from filed data
The March 25 press release, issued the day the 20-F carried the auditor’s going-concern paragraph, is headlined “Company well funded through planned NS002 pivotal study and potential NDA submission” and says the Phase 2 results show “potential for best-in-class epinephrine delivery”. Later releases describe “a growing $2 billion market opportunity”. Both are the company’s own words in releases furnished on Form 6-K; the releases give no source for the market figure, and this page does not use it. The anaphylaxis statistics in the Need section are third-party figures as cited in the 20-F and have not been verified here. The device image in the Platform section comes from the company’s website; the laboratory-model bars restate figures from the 20-F. 6-K, Mar 25, 2026 6-K, Jul 28, 2026 6-K, Aug 17, 2026 6-K, Sep 14, 2026 20-F
Governance
Board, ownership, the October 8 meeting and the auditor
Roles are from the 20-F table of directors and the proxy statement filed Sep 4, 2026. No portraits are used on this page.
| Director | Role as filed | Term |
|---|---|---|
| Udi Gilboa | Co-Founder and Executive Chairman; marked as a service provider | Class III, to 2028 |
| Dr. Dalia Megiddo | Co-Founder, Director, Chief Development Officer and Chief Medical Officer; marked as a service provider | Class III, to 2028 |
| Brendan P. O’Grady | Chief Executive Officer from Jul 27, 2026; listed by the proxy as a Class III director | Class III, to 2028 |
| Dr. Ronnie Hershman | Director; independent under NYSE American rules; compensation committee | Class II, to 2027 |
| Isaac Israel | Director; independent; audit and compensation committees | Class II, to 2027 |
| David Silberman | Director; independent; audit committee | Class I, expires at the Oct 8 meeting |
| Dr. Sharon Shacham | Director; independent; audit and compensation committees | Class I, expires at the Oct 8 meeting |
| Holder | Shares | Share |
|---|---|---|
| Udi Gilboa | 1,942,446 | 16.6% |
| Dr. Dalia Megiddo | 1,894,068 | 16.2% |
| Dr. Ronnie Hershman | 1,419,451 | 12.1% |
| Atlas Private Holdings (Cayman) Ltd. | 1,796,946 | 9.9% |
| All 8 directors and executive officers | 5,391,736 | 45.9% |
From the 20-F, as of March 25, 2026, after the February 2026 private placement. Counts include shares issuable on warrants and on options exercisable within 60 days; Atlas’s count is 898,473 shares plus 898,473 warrant shares, and its percentage reflects a 9.99% limit on the warrants. Hershman Holdings LLC held 927,126 shares (7.8%), also counted in Dr. Hershman’s total. The group of 8 includes Mr. Teleman and Mr. Rubin, who have since left their roles, and not Mr. O’Grady. The interim statements’ related-party note gives Mr. Gilboa and Dr. Megiddo “approximately 16%” each and Dr. Hershman “approximately 8%” at June 30, 2026; the filings do not reconcile that with the table. 6-K
Annual and special general meeting: five proposals
- Re-appoint Brightman Almagor Zohar & Co., a member firm of the Deloitte Global Network, as independent auditor and let the board set its remuneration.
- Re-appoint David Silberman and Dr. Sharon Shacham as Class I directors for three years, to the 2029 meeting.
- Approve the compensation package of CEO Brendan P. O’Grady.
- Approve a one-time bonus of $70,000 for former CEO Dan Teleman, part of a $100,000 bonus.
- Raise the shares reserved for incentive stock options under the U.S. sub-plan of the 2019 Incentive Option Plan from 105,611 to 305,611.
Proposals 3 and 4 need a “Special Majority” as the proxy statement defines it. The financial statements are also on the agenda for discussion only. The meeting had not been held at the time of the latest filing reviewed. 6-K, Sep 4, 2026
Auditor: Brightman Almagor Zohar & Co., a member firm of the Deloitte Global Network, since 2024 (PCAOB ID 1197). Its report on the FY2025 financial statements includes the going-concern paragraph quoted in the disclosures.
Filings
The filings behind this page
Dates are EDGAR filing dates; event dates are in the descriptions. These are the principal filings behind the figures on this page, newest first.
| Filed | Form | What it reports |
|---|---|---|
| Sep 18, 2026 | 6-K | At-the-market sales agreement with BTIG, LLC (Sep 18, 2026). Open |
| Sep 14, 2026 | 6-K | FDA clears the IND for NS002; pivotal study planned (press release of Sep 14, 2026). Open |
| Sep 4, 2026 | 6-K | Notice, proxy statement and proxy card for the Oct 8, 2026 annual and special general meeting. Open |
| Aug 19, 2026 | 6-K | CFO resignation effective Sep 18, 2026; interim CFO named (Aug 19, 2026). Open |
| Aug 17, 2026 | 6-K | Interim statements, MD&A and press release for the six months ended Jun 30, 2026 (Aug 17, 2026). Open |
| Jul 28, 2026 | 6-K | CEO transition: Brendan P. O’Grady appointed, Dan Teleman resigns (Jul 28, 2026). Open |
| Jun 9, 2026 | 6-K | NS003 preclinical pharmacokinetic and safety results (Jun 9, 2026). Open |
| Mar 25, 2026 | 6-K | Annual results press release and business update (Mar 25, 2026). Open |
| Mar 25, 2026 | 20-F | Annual report for FY2025, with the auditor’s going-concern paragraph. Open |
| Mar 16, 2026 | 6-K | Phase 2 topline results for NS002 (Mar 16, 2026). Open |
| Mar 6, 2026 | 6-K | Amended and restated articles of association, as amended Mar 5, 2026. Open |
| Feb 13, 2026 | 6-K | Closing of the $15.0 million private placement (Feb 13, 2026). Open |
| Feb 12, 2026 | 6-K | Securities purchase agreement for the private placement (Feb 10, 2026). Open |
| Jan 20, 2026 | 6-K | Interim Phase 2 results for NS002 (Jan 20, 2026). Open |
| Dec 29, 2025 | 6-K | Unaudited interim financial statements as of Jun 30, 2025. Open |
| Dec 22, 2025 | 6-K | Letter to shareholders from the CEO (Dec 22, 2025). Open |
| Nov 20, 2025 | 6-K | Appointment of Eyal Rubin as Chief Financial Officer (Nov 20, 2025). Open |
| Nov 18, 2025 | 6-K | First participant dosed in the Phase 2 study of NS002 (Nov 18, 2025). Open |
| Oct 8, 2025 | 6-K | New master services, schedule of work and supply agreements with Aptar France (Oct 8, 2025). Open |
Investor alerts. The company’s investor relations site lists its events and news on ir.nasuspharma.com. This concept page does not collect or store email addresses.
Contact
Investor relations
Telephone
+972.3.573.6632Mailing address
Nasus Pharma LtdP.O. Box 284
Tel Aviv, Israel 6100201
Investor page
ir.nasuspharma.comFilings
SEC EDGAR, CIK 0002029039The investor email is published in the company’s press releases. The mailing address and telephone are from the 20-F, which says the company is “currently a virtual company”.